
China approves first homegrown HPV vaccine
pharmafile | January 8, 2020 | News story | Research and Development, Sales and Marketing | China, HPV, NMPA, pharma, vaccines
Female patients in China between the ages of nine and 45 will have access to the country’s first domestically-produced vaccine for the prevention of cancerogenic human papillomavirus (HPV) after the approval of Innovax’s Cecolin therapy by the National Medical Products Administration (NMPA).
Cecolin protects against Type 16 and 18 HPV, the two most common strains of the virus that can lead to cervical cancer. The approval presents an alternative therapy in a space occupied by only two other countries worldwide: GlaxoSmithKline, headquartered in the UK which produces a two-valent vaccine, and MSD in the US, which produces a four- and nine-valent vaccine.
According to the NMPA, the move was made in response to rising public demand for a HPV vaccine in order to generate greater access. The country said it would aim to accelerate the review and approval of domestically produced HPV vaccines.
The development is emblematic of a concerted effort from China to reduce its reliance on importing medicine from outside its borders and follows within a week the news that the NMPA had approved its first homegrown 13-valent pneumonia vaccine.
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …






